- Home
- LFCR vs SERA Comparison
LFCR vs SERA Comparison
Compare LFCR & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFCR
- SERA
- Stock Information
- Founded
- LFCR 1986
- SERA 2008
- Country
- LFCR United States
- SERA United States
- Employees
- LFCR N/A
- SERA N/A
- Industry
- LFCR Biotechnology: Pharmaceutical Preparations
- SERA Precision Instruments
- Sector
- LFCR Health Care
- SERA Health Care
- Exchange
- LFCR Nasdaq
- SERA Nasdaq
- Market Cap
- LFCR 224.6M
- SERA 208.7M
- IPO Year
- LFCR N/A
- SERA 2021
- Fundamental
- Price
- LFCR $6.55
- SERA $4.10
- Analyst Decision
- LFCR Buy
- SERA
- Analyst Count
- LFCR 3
- SERA 0
- Target Price
- LFCR $8.00
- SERA N/A
- AVG Volume (30 Days)
- LFCR 128.0K
- SERA 113.4K
- Earning Date
- LFCR 01-02-2025
- SERA 05-07-2025
- Dividend Yield
- LFCR N/A
- SERA N/A
- EPS Growth
- LFCR N/A
- SERA N/A
- EPS
- LFCR N/A
- SERA N/A
- Revenue
- LFCR $130,858,000.00
- SERA $94,000.00
- Revenue This Year
- LFCR $2.24
- SERA N/A
- Revenue Next Year
- LFCR $7.88
- SERA $3,081.82
- P/E Ratio
- LFCR N/A
- SERA N/A
- Revenue Growth
- LFCR 16.47
- SERA N/A
- 52 Week Low
- LFCR $3.68
- SERA $3.84
- 52 Week High
- LFCR $8.00
- SERA $12.36
- Technical
- Relative Strength Index (RSI)
- LFCR 61.32
- SERA 36.60
- Support Level
- LFCR $6.00
- SERA $3.91
- Resistance Level
- LFCR $6.58
- SERA $4.34
- Average True Range (ATR)
- LFCR 0.28
- SERA 0.24
- MACD
- LFCR 0.10
- SERA 0.10
- Stochastic Oscillator
- LFCR 88.24
- SERA 28.44
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.